Praxis Precision Medicines, Inc. - 8-K Filing
Praxis Precision Medicines entered into a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for delivering ulixacaltamide, targeting essential tremor. The partnership aims to expand the drug's reach and competitive positioning while extending its long-term value; Praxis also made an equity investment in Remagine. (Items: 8.01 Other Events)
Tickers: $PRAX